humira depend lessen pipelin nilex
rais sales/ep vs
street model
vs street humira ex-u leakag biosimilar
off-set gm tailwind royalti phase orilissa/upad/risa
add increment sale coupl imbruvica/venclexta
label expans lessen humira depend expect orilissa
launch acceler access/dtc kick-in expect use
dri powder reiter ep support
dcf
rais sales/ep
abbv midpoint vs street
higher imbruvica sale higher oper margin vs street
model total revenu yoy mostli in-
line street ep street
mostli higher oper margin vs think
humira ex-u leakag larg off-set gross margin improv
humira royalti stack fulli phase yoy tailwind
posit deliv double-digit ep growth project
orlissa launch upadacitinib/risankizumab launch add
increment sale allow immunolog franchis grow
ex-u humira loe hem/onc assum imbruvica/venclexta
contribut increment sale label expans extend abbv
leadership view orilissa launch in-lin expect broader
formulari coverag dtc kick-in mavyret deliv meteor growth
yoy expect competit declin hcv patient start
headwind abbv free cash flow gener provid flexibl
creat sharehold valu dividend growth share repurchas
accret note oct click dri
powder ceo note look biotech valuat although
theyv come theyr still valu pretti highli reiter buy/
ep support dcf risk clinic regulatori
regulatori action orilissa uptak humira ip challeng price risk
tr target
humira us growth offset ex-u declin due biosimilar
humira perform continu robust brand post yoy growth
last four quarter view humira us market primarili volume-driven growth stori
expect dynam continu half humira yoy
growth driven volum mid-singl digit price contribut humira us price
benefit ceo comment lower end mid-singl digit probabl reason
expect ex-u market set expect declin humira
sale base biosimilar discount came point higher abbv base case plan
scenario state previous see note titl thought humira biosimilar hcv market
 cfo departur lower pt four biosimilar launch europ price discount
rang expect humira ex-u declin rate step
note biosimilar discount nordic tender countri
come high repres humira ex-u busi plan
fine-tun humira ex-u declin expect base dynam remain
busi still undergo negoti left humira global sale mostli
unchang in-lin abbv project slightli street
lower humira global sale yoy faster ex-u sale eros
yoy vs previous humira sale slightli street
upuda/risa launch off-set humira ex-u declin
posit launch next-gener immunolog asset upadacitinib upad
risankizumab risa conting regulatori approv action note
call launch upad/risa give us three four year ramp opportun drive
signific uptak two therapi prior expect entri direct biosimilar competit
 track file regulatori submiss upadacitinib rheumatoid arthriti ra
approv expect file risankizumab psoriasi pso us/eu
april/may regulatori action geographi expect remind upad
 risa demonstr robust efficaci lead indic rheumatoid arthriti ra see
note psoriasi pso see note respect also comprehens on-going clinic
develop plan across sever indic drive growth out-year upad
four on-going trial psoriat arthriti atop dermat ad crohn diseas cd
ulcer coliti uc intend initi sixth indic giant cell arthriti
risa on-going trial crohn diseas intend initi
model risa/upad sale materi street
immunolog pipelin make progress clinic
addit near-term opportun upad risa highlight novel early-
stage immunolog asset think could contribut franchis growth out-year conting
posit data abbv combin btk inhibitor
inhibitor undergo phase studi rheumatoid arthriti ra primari complet
also aim initi lupu studi also initi
studi antagonist ulcer coliti oct primari complet
dec abbv anti-tnf steroid antibody-drug conjug evalu
multi-dos phase studi plan initi studi treatment
ra
imbruvica growth driven cll uptak label expans
imbruvica market leader chronic lymphocyt leukemia cll although imbruvica current
cll market leadership driven monotherapi use bendamustine/rituximab combo use
older patient partner johnson johnson rate focus drive deeper
penetr combin cll treatment ii young fit patient watch
wait cll patient fda accept abbv snda imbruvica gazyva regimen cll patient
prioriti review oct base result illumin studi fda action
expect mid-april anoth key studi support deeper imbruvica penetr cll
allianc cooper group studi show imbruvica alon combo rituximab
shower superior vs soc bendamustin yr patient imbruvica ritxumab approv
waldenstrom macroglobulinemia wm aug mark fda approv imbruvica ad
page
modest leg growth on-going clinic trial involv imbruvica accord
clinicaltri gov includ trial model imbruvica risk-adjust sale
street
venclexta ramp r/r cll aml/mm multi-billion oppi
venclexta global sale us ex-u ramp acceler
due launch broader relapsed/refractori cll set regardless delet june
base murano data see note titl venclexta approv broader r/r cll use base
murano data partner roch rog-ch rate aim establish venclexta
foundat chemo-fre option cll abbv/roch plan file approv venclexta
gazyva cll come month base posit result studi aml
fda action acceler approv venclexta set patient cant receiv high-
dose induct chemo expect confirmatori data expect base
present aml common older patient estim chemo-unfit patient
account roughli half treat aml patient potenti higher address market
includ patient pretreat venclexta prior induct chemotherapi order curtain diseas
activ addit result bellini studi evalu venclexta velcad dexamethason
r/r multipl myeloma expect abbv/roch also plan initi mm studi
venclexta note call aml mm sizeabl indic
repres multibillion dollar peak sale opportun model venclexta global sale
orilissa uptak improv formulari coverage/dtc
orilissa elagolix launch us treatment endometriosi aug see note
titl orilissa elagolix approv clean label endometriosi howev note earlier
see note orilissa us launch endometriosi slow start total trx two month
launch aug sep per iqvia data note howev orilissa launch
track right in-lin assumpt remind project orilissa sale
juli vs our/street think orilissa secur formulari coverag
expect broad coverag sale growth like acceler addit cfo
note seen year start-up full dtc campaign given dramat
under-penetr endometriosi market per market model diagnos
dx patient treat non-surg expect abbv orilissa dtc campaign
meaning tailwind brand especi combin greater market access
also expect file orilissa uterin fibroid add anoth leg growth
beyond base obgyn market model think orilissa reach us sale less
patient share endometriosi uterin fibroid uf market materi upsid
dx treatment rate experi step-chang increas due increas avail non-surg
option model orilissa sale vs street
hcv sale comp shrink patient pool
help secur market share global within month launch lead meteor
increas sale yoy howev intens competit hcv market
character price compress formulari setback well declin patient pool suggest
mavyret global sale like peak exampl express script esrx buy dave
macdonald caremark buy dave macdonald exclud mavyret formulari
put pressur abil grow mavyret commerci channel assum
need discount mavyret price tag gilead rate price epclusa/
harvoni author gener expect enter market jan addit price
volum pressur global hcv market model project patient start declin
chang expect hcv sale vs our/street howev
model hcv global sale yoy in-lin street model hcv
global sale street
immunology/oncolog catalyst key focu
expect boehring ingelheim follow biosimilar manufactur sandoz subsidiari
novarti nv rate freseniu kabi fre-d rate settl pend global humira
patent litig near-term also expect showcas imbruvica/venclexta
page
clinic dataset upcom confer san diego ca dec varieti
imbruvica studi on-going differ cll sub-popul young fit wait watch patient etc
begin read next set venclexta catalyst includ approv aml
expect end ii phase multipl myeloma mm read-out pipelin
look submit upadacitinib nda file approval/launch assum
file risankizumab psoriasi us fda apr eu ema may expect fda/
ema action abbv replic trial orilissa uterin fibroid elari
produc posit result mid-march expect data snda file
next key catalyst rova-t result phase meru studi sclc late
exhibit full catalyst calendar
page
 sale
sg sale
impli us ex-u rang
page
sale
sale
page
exhibit estim strh vs consensu
page
exhibit pipelin strh vs
page
exhibit in-lin product strh vs
page
late earli
late earli
late earli
file upadacitinib rheumatoid arthriti
ema approv broad r/r cll base murano data
regulatori approv expect aml patient receiv high-dos induct therapi
file us/eu pso apr base result immvent immhanc
start phase
start mm w/ mutat
data bellini r/r mm
fda deadlin releas interchang guidelin biosimilar
fda approv expect imbruvica gazyva cll/sll base data prioriti review
start axial spa gca
start see data rova-t combin opdivo/ yervoy
regulatori approv expect rheumatoid arthriti ra
taho trial second-lin small cell lung cancer sclc
meru trial first-lin small cell lung cancer sclc
page
million
sale
sale
page
million
equival
defer tax receiv
net properti equip
account payabl accru liabil
current matur lt debt
accumul comprehens incom loss
total liabil equiti
page
exhibit statement flow
million
flow oper activ
depreci amort
chang asset liabil
net cash use oper activ
flow invest activ
purchas properti equip
acquisit invest net cash acquir
decreas increas restrict cash invest
decreas increas market secur net
net cash use invest activ
flow financ activ
proce repay short-term debt
proce issuanc long-term debt
repay long-term debt net
purchas common share
proce stock option exercis
net cash flow provid financ activ
effect fx cash cash equival
net increas decreas cash cash equival
cash equival begin period
cash equival end period
page
inc highli focus research-driven biopharmaceut compani discov
develop deliv innov therapi treat health issu rang life-threaten ill
chronic condit gener total net sale sale deriv
us intern market compani core area expertis immunolog
hematology/oncolog virolog neurosci gener medicin
humira largest pharmaceut product histori biopharmaceut industri
total revenu come differ indic abbv second largest franchis hematology/
oncolog imbruvica/venclexta franchis account sale abbv
virolog franchis includ hepat product viekira/mavyret account
sale
rate buy one favorit valu name large-cap biopharmaceut
sinc launch believ time humira loss exclus us along
pipelin underappreci street thesi base humira us
exclus allow extract maximum valu franchis asset
diversifi revenu stream hematology/oncolog immunolog pipelin humira
ideal posit us volum driven growth price leverag well margin expans
think evolv legal regulatori landscap suggest us humira biosimilar competit
delay januari due long date humira patent estat global immunolog market
model assum biosimilar competit us earli legal catalyst around humira play
expect street push biosimilar entri us toward earli estim put
upward pressur street consensu humira sale estim
pipelin ideal posit view extern collabor intern
deriv asset provid next gener therapi autoimmun disord improv upon
humira best class profil posit leverag global humira infrastructur
pipelin immunolog asset includ upadacitinib select oral inhibitor risankizumab
monoclon antibodi target also posit reduc humira biosimilar risk
maxim hematology/oncolog franchis includ imbruvica venclexta hematolog
malign rova-t solid tumor
valuat risk
price target assum trade ep premium major
biopharmaceut peer group support dcf wacc termin growth expect
trade premium group settl us patent disput humira pipelin
matur multipl data read out immunolog hematolog oncolog asset play
model assum humira total sale account sale immunolog
 hematology/oncolog sale new product label expans exist asset rise
sale
risk rate price target includ earlier expect humira biosimilar competit
us market addit assum compani abl gener revenu
pipelin lower humira total revenu clinic regulatori
commerci setback key pipelin asset upadacitinib risankizumab imbruvica venclexta rova-
etc could forc look extern acceler diversif sale prior humira loss
exclus us invest risk relat pharmaceut industri gener includ
continu price risk payer especi europ polit risk product develop risk
regulatori risk commerci risk legal risk patent challeng
compani mention note
freseniu se co kgaa fre-d rate
inc rate
johnson johnson rate
page
novarti ag nv rate
roch hold ltd genusssch rog-ch rate
john bori herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
